重酒石酸卡巴拉汀(Rivastigmine Tartrate) - 药物靶点：AChE_在研适应症：非典型进行性核上性麻痹，阿尔茨海默病引起的痴呆症，帕金森病所致痴呆_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Rivastigmine、rivastigmine hydrogen tartrate、Rivastigmine transdermal patch

+ [20]

靶点

AChE

作用机制

AChE抑制剂(乙酰胆碱酯酶抑制剂)

治疗领域

神经系统疾病内分泌与代谢疾病眼部疾病+ [1]

在研适应症

非典型进行性核上性麻痹阿尔茨海默病引起的痴呆症帕金森病所致痴呆+ [3]

非在研适应症

创伤性脑损伤认知障碍认知功能障碍+ [4]

原研机构

Novartis Pharma AG

在研机构

Novartis Europharm Ltd.Sandoz GmbHActavis Group PTC ehf.

+ [14]

非在研机构

Novartis AG

Novartis Pharmaceuticals Corp.Teva Pharmaceuticals Europe BV

+ [1]

最高研发阶段批准上市

首次获批日期

欧盟 (1998-05-11),

阿尔茨海默症痴呆帕金森病

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构

分子式C18H28N2O8

InChIKeyGWHQHAUAXRMMOT-MBANBULQSA-N

CAS号129101-54-8

关联

142

项与重酒石酸卡巴拉汀相关的临床试验

NCT06382649 / Not yet recruiting临床2期IIT

Rivastigmine for Antimuscarinic Delirium: a Randomized, Placebo-controlled Trial

Antimuscarinic delirium (AMD) is a common and dangerous toxicology condition caused by poisoning by medications and other chemicals that block muscarinic receptors. Physostigmine, the standard antidote for AMD, currently has very limited availability in the United States due to an interruption of production.
Recent case reports and small observational studies suggest that rivastigmine might be useful in the treatment of AMD, but there is not direct prospective evidence comparing rivastigmine to physostigmine or supportive care. In order to investigate the effectiveness of rivastigmine, the investigators propose a randomized, placebo-controlled clinical trial of rivastigmine for AMD. The investigators hypothesize that patients treated with rivastigmine for antimuscarinic delirium will experience more rapid resolution of agitation and delirium than those treated with placebo.

开始日期2025-11-01

申办/合作机构

Washington University School of Medicine

[+1]

NCT06399679 / Recruiting临床2期IIT

Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium After Initial Control With Physostigmine (RIVA-AP): a Randomized, Placebo-controlled Trial

Antimuscarinic delirium (AMD) is a common and dangerous toxicology condition caused by poisoning by medications and other chemicals that block muscarinic receptors. Physostigmine is effective in reversing AMD but has a short duration of action, and patient commonly experience recurrence of AMD after initial control with physostigmine.
Recent case reports and small observational studies suggest that rivastigmine, which has a longer duration of action than physostigmine, might be useful in the treatment of AMD. In order to investigate the effectiveness of rivastigmine in preventing recurrence of AMD after initial control with physostigmine, the investigators propose a randomized, placebo-controlled clinical trial of rivastigmine for AMD. The investigators hypothesize that patients treated with rivastigmine after initial control of AMD with physostigmine will experience less recurrence of antimuscarinic delirium than those treated with placebo.

开始日期2024-11-04

申办/合作机构

Washington University School of Medicine

[+1]

IRCT20130719014054N3 / Recruiting临床3期IIT

A randomized clinical trial study on the safety and efficacy of rivastigmine on cognitive function in HIV infected patients

开始日期2024-08-05

申办/合作机构

Tehran University of Medical Sciences

100 项与重酒石酸卡巴拉汀相关的临床结果

登录后查看更多信息

100 项与重酒石酸卡巴拉汀相关的转化医学

登录后查看更多信息

100 项与重酒石酸卡巴拉汀相关的专利（医药）

登录后查看更多信息

2,145

项与重酒石酸卡巴拉汀相关的文献（医药）

2025-02-01·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of novel hybrid tryptamine-rivastigmine molecules as potent AChE and BChE inhibitors exhibiting multifunctional properties for the management of Alzheimer's disease

Article

作者: Kumar, Prabhat ; Shankar, Gauri ; Ghosh, Aparajita ; Kulkarni, Onkar ; Modi, Gyan ; Garg, Prabha ; Srikrishna, Saripella ; Wani, Mushtaq Ahmad ; Kumar, Sunil ; Kumar, Saroj ; Mandloi, Upesh ; Rai, Sanskriti ; Varma, Tanmaykumar ; Singh, Gireesh Kumar

Contemporary research evidence has corroborated a gradual loss of central cholinergic neurons in Alzheimer's Disease (AD). This progressive deterioration leads to cognitive dysfunction and impaired motor activity, culminating in the brain cell's death in the disease. The approved drugs for AD treatment can only offer relief from symptoms without addressing the underlying pathological hallmarks of the disease. To address the limitations associated with rivastigmine (RIV), a marketed drug for AD, a series of tryptamine derivatives was designed, synthesized, and evaluated in various in-vitro and in-vivo AD models. Enzyme inhibition studies identified compounds 6d and 6e as the lead molecules with potent inhibitors against AChE (6d, IC₅₀: 0.99 ± 0.009 nM and 6e IC₅₀: 7.97 ± 0.016 nM and BChE (6d, IC₅₀: 27.79 ± 0.21 nM and 6e, IC₅₀: 0.79 ± 0.005 nM), compared to the marketed drug Riv (AChE, IC₅₀: 6630 ± 0.76 nM, BChE IC₅₀ = 91 ± 0.40 nM). The molecular docking and dynamics studies corroborated the enzyme inhibition studies. The PAMPA assay strongly suggested the BBB crossing ability of the lead molecules. Further, 6d and 6e demonstrated the capability to counteract oxidative stress and Aβ_1-42 in various in-vitro studies. Compound 6e exhibited remarkable radical scavenging activity in the DPPH assay (IC₅₀: 22.91 ± 1.73 μM) compared to rivastigmine (% radical scavenging activity: 3.71 ± 0.09 at 200 μM). Interestingly, 6d and 6e exhibited promising activity in the AD Drosophila model by protecting eye phenotypes from degeneration induced by Aβ_1-42 toxicity and reduced mitochondrial and cellular oxidative stress in this model. Furthermore, upon oral administration, 6d and 6e could reverse scopolamine-induced amnesia by improving spatial and cognitive memory in mice at 0.3 and 0.5 mg/kg compared to rivastigmine at 3 mg/kg and were found to have potent ex-vivo anti-ChEs properties, which are correlated with the observed pro-cognitive effects in the Morris Water Maze, likely mediated through the inhibition of both cholinesterases. The expression of various neuroprotection markers, such as BDNF and TRKB, was significantly overexpressed compared to the disease control group.

2025-01-01·JOURNAL OF INORGANIC BIOCHEMISTRY

Exploiting the potential of rivastigmine-melatonin derivatives as multitarget metal-modulating drugs for neurodegenerative diseases

Article

作者: Bon, Leo ; Dias, Inês ; Sanna, Daniele ; Guerreiro-Oliveira, Catarina ; Borges, Fernanda ; Santos, M. Amélia ; Cardoso, Sandra M ; Chavarria, Daniel ; Cardoso, Sandra M. ; Chaves, Sílvia ; Garribba, Eugenio ; Banas`, Angelika ; Santos, M Amélia ; Banas, Angelika

The multifaceted nature of the neurodegenerative diseases, as Alzheimer's disease (AD) and Parkinson's disease (PD) with several interconnected etiologies, and the absence of effective drugs, led herein to the development and study of a series of multi-target directed ligands (MTDLs). The developed RIV-IND hybrids, derived from the conjugation of an approved anti-AD drug, rivastigmine (RIV), with melatonin analogues, namely indole (IND) derivatives, revealed multifunctional properties, by associating the cholinesterase inhibition of the RIV drug with antioxidant activity, biometal (Cu(II), Zn(II), Fe(III)) chelation properties, inhibition of amyloid-β (Aβ) aggregation (self- and Cu-induced) and of monoamine oxidases (MAOs), as well as neuroprotection capacity in cell models of AD and PD. In particular, two hybrids with hydroxyl-substituted indoles (5a2 and 5a3) could be promising multifunctional compounds that inspire further development of novel anti-neurodegenerative drugs.

2025-01-01·CARBOHYDRATE POLYMERS

Supramolecular cyclodextrin-based reservoir as nasal delivery vehicle for rivastigmine to brain

Article

作者: Zhang, Jiwen ; Xu, Huipeng ; Lv, Yuting ; Wang, Manli ; Wang, Siwen ; Zhang, Guoqing ; Wu, Wenting ; Wu, Li ; Zhao, Xiangyu ; Wang, Caifen ; Zhu, Weifeng

The purpose of this study involved the synthesis of supramolecular reservoir (i.e. cyclodextrin metal-organic framework, MOF) using cyclodextrins as building blocks, followed by cross-linking to obtain crosslinked CD framework (CDF) using CD-MOF as template and functionalized with borneol (BO) to enhance rivastigmine (RIV) permeation and facilitate brain targeting via intranasal administration. Utilizing BO modified CDF (BO-CDF) with cubic shape as a carrier for the encapsulation of RIV, a nasal RIV delivery system (RIV@BO-CDF) was fabricated. The particle size of RIV@BO-CDF was approximately 250 nm, and the drug loading capacity reached 15 ± 2 %. BO-CDF improved the mucoadhesion and enhanced RIV permeability with the plasma concentration-time curve (AUC), the brain AUC and the peak drug concentration within brain in rats 1.7, 2.3 and 8 times than that of oral RIV solution, respectively. The relative drug targeting efficiency percentage (DTE, 139.4 %) and direct drug transfer percentage (DTP, 28.3 %) of RIV@BO-COF indicated good targeting efficiency and direct nose-to-brain drug delivery. Overall, this study provides a potential application of supramolecular cyclodextrin-based reservoir to enhance the brain targeting and efficacy of the RIV via nasal delivery.

167

项与重酒石酸卡巴拉汀相关的新闻（医药）

2024-12-16

·alphacognition.com

Alpha Cognition Announces Partial Exercise of Over-Allotment Option

VANCOUVER, British Columbia and Dallas, TX — December 16, 2024 (BUSINESS WIRE) — Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced that the underwriters of its underwritten U.S. public offering (the “Offering”) have partially exercised their over-allotment option to purchase an additional 488,506 common shares at the public offering price of US$5.75 per share for an additional US$2.8 million in gross proceeds. After giving effect to the partial exercise of the over-allotment option, the Company sold an aggregate 9,184,159 common shares for gross proceeds of approximately US$52.8 million, before deducting underwriter discounts and other related expenses. The option closing date was December 16, 2024. The common shares began trading on The Nasdaq Capital Market on November 12, 2024, under the ticker symbol “ACOG”. The Company intends to use the proceeds towards the commercialization and launch of ZUNVEYLTM in Alzheimer’s Disease, further research and development of its pipeline product candidates, continued commercial CMC activities (chemistry, manufacturing, and controls), and for working capital and general corporate purposes. Titan Partners Group, a division of American Capital Partners, is acting as Sole Bookrunner for the offering. The securities were sold pursuant to a registration statement on Form S-1 (File No. 333-280196) relating to these securities and a related registration statement on Form S-1 MEF that became effective upon its filing in accordance with Rule 462(b) under the Securities Act of 1933, as amended. The Offering is being made only by means of a prospectus. A copy of the final prospectus related to the Offering may be obtained from Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 29th Floor, New York, NY 10007, or via email at prospectus@titanpartnersgrp.com or telephone at (929) 833-1246. In addition, a copy of the final prospectus relating to the Offering may be obtained via the SEC's website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it improves the function of neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. Benzgalantamine is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. Forward-looking Statements This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the potential use of proceeds of the Offering. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future. Contacts For further information: Michael McFadden, CEO Tel: 1-858-344-4375 info@alphacognition.com Titan Partners Contact: Tel: (929) 833-1246 info@titanpartnersgrp.com.

临床研究

2024-12-12

·Business Wire

Alpha Cognition Announces Voluntary Delisting from CSE

VANCOUVER, British Columbia & DALLAS--( BUSINESS WIRE )-- Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, or the “Company”), announces that in connection with the Company’s listing on the Nasdaq Capital Market the Company will voluntarily delist its common shares from the Canadian Securities Exchange. The shares will be delisted from the Canadian Securities Exchange at the close of trading on December 17, 2024. The Company’s common shares will continue to trade on the Nasdaq under the symbol “ACOG”. About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it improves the function of neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. Benzgalantamine is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. Forward-looking Statements: This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future.

上市批准

2024-12-11

·Business Wire

Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

VANCOUVER, British Columbia & DALLAS--( BUSINESS WIRE )--Alpha Cognition Inc. (Nasdaq: ACOG) (CSE: ACOG) (“Alpha Cognition” [ACI], or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced interim preclinical data that supports the continued development of ALPHA-1062 for the treatment of mild traumatic brain injury (mTBI). The interim data provides evidence of benefit for ALPHA-1062, in the treatment of mTBI resulting from repetitive blast trauma, a highly relevant military injury. Blast caused mTBI is considered to be the signature injury effecting soldiers where brain injury from explosive devices and artillery fire blast exposure is highly prevalent. ACI previously documented extensive functional and neuropathological protection, provided by ALPHA-1062 administration, following a single moderate traumatic brain injury. This second pre-clinical study in a rodent model, supported by the US Department of Defense (DOD), is a collaboration with investigators at the Seattle Institute of Biomedical and Clinical Research (affiliated with both the University of Washington and the Veterans Administration). The study is ongoing, with interim data demonstrating that ALPHA-1062 administration following 3 consecutive days of blast induced mTBI, results in a reduction of TBI associated neuropathology. Key findings demonstrated that, ALPHA-1062 administration reduced levels of neuroinflammation markers and neuropathology that occurs after blast trauma. High dose ALPHA-1062 reduced the levels of myeloid cell activation [CD 68] across multiple brain regions one month after blast. High dose ALPHA-1062 also demonstrated the ability to reduce midbrain astrogliosis [GFAP]. Astrogliosis is a process where brain cells called astrocytes become larger, multiply, and change in response to injury or disease in the brain. “These outcomes indicate a protective effect of ALPHA-1062, and demonstrated a reduction of neuropathology. The data provide further support for the continued development of ALPHA-1062 for the treatment of acute mild traumatic brain injury,” said Denis Kay, ACI’s Chief Scientific Officer. Further analysis of neuropathology and neurobehavioral [functional recovery] data is ongoing with the final study report due Q2/2025. About Alpha Cognition Inc. Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ALPHA-1062, is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ALPHA-1062’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia. An intranasal formulation of ALPHA-1062 has demonstrated potent preservation brain structure and function in a preclinical model of moderate TBI, where enhanced recovery from the brain injury was also seen. The intranasal formulation is currently being evaluated for its ability to provide protection from a military relevant model of repeated mild TBI, in a program sponsored by the US Department of Defense. Neither Canadian Securities Exchange (the “CSE”) or the OTC Markets Group, accepts responsibility for the adequacy or accuracy of this release. Forward-looking Statements This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the TBI out-licensing plan and associated financing, the availability of funding pursuant to financings, the Company’s business strategy, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the Company’s products. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future.

100 项与重酒石酸卡巴拉汀相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02558	重酒石酸卡巴拉汀	N06DA03	DB00989

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
非典型进行性核上性麻痹	美国	Sandoz, Inc.	2007-07-06
阿尔茨海默病引起的痴呆症	欧盟	Almirall SA	1998-12-04
阿尔茨海默病引起的痴呆症	冰岛	Almirall SA	1998-12-04
阿尔茨海默病引起的痴呆症	列支敦士登	Almirall SA	1998-12-04
阿尔茨海默病引起的痴呆症	挪威	Almirall SA	1998-12-04
帕金森病所致痴呆	欧盟	Almirall SA	1998-12-04
帕金森病所致痴呆	冰岛	Almirall SA	1998-12-04
帕金森病所致痴呆	列支敦士登	Almirall SA	1998-12-04
帕金森病所致痴呆	挪威	Almirall SA	1998-12-04
阿尔茨海默症	欧盟	Novartis Europharm Ltd.	1998-05-11
阿尔茨海默症	冰岛	Novartis Europharm Ltd.	1998-05-11
阿尔茨海默症	列支敦士登	Novartis Europharm Ltd.	1998-05-11
阿尔茨海默症	挪威	Novartis Europharm Ltd.	1998-05-11
痴呆	欧盟	Novartis Europharm Ltd.	1998-05-11
痴呆	冰岛	Novartis Europharm Ltd.	1998-05-11
痴呆	列支敦士登	Novartis Europharm Ltd.	1998-05-11
痴呆	挪威	Novartis Europharm Ltd.	1998-05-11
帕金森病	欧盟	Novartis Europharm Ltd.	1998-05-11
帕金森病	冰岛	Novartis Europharm Ltd.	1998-05-11
帕金森病	列支敦士登	Novartis Europharm Ltd.	1998-05-11

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
谵妄	临床3期	法国	Novartis Pharmaceuticals Corp.	2011-06-01
苏醒期谵妄	临床3期	瑞士	Novartis AG	2006-01-01
神经行为学表现	临床3期	-	Novartis AG	2003-01-01
创伤性脑损伤	临床3期	-	Novartis AG	2002-11-01
认知功能障碍	临床3期	-	Novartis AG	2002-11-01
血管性痴呆	临床3期	美国	Novartis Pharmaceuticals Corp.	2001-08-01
血管性痴呆	临床3期	奥地利	Novartis Pharmaceuticals Corp.	2001-08-01
血管性痴呆	临床3期	加拿大	Novartis Pharmaceuticals Corp.	2001-08-01
血管性痴呆	临床3期	法国	Novartis Pharmaceuticals Corp.	2001-08-01
血管性痴呆	临床3期	德国	Novartis Pharmaceuticals Corp.	2001-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02989402 (CTgov)	临床4期	阿尔茨海默病引起的痴呆症	100	Rivastigmine	壓積繭壓醖積鹹選蓋醖(構鬱齋膚範壓齋憲鹽範) = 觸窪鬱鏇糧繭艱鏇選鹹蓋獵夢廠餘衊繭簾鹽鹽 (鑰蓋鏇餘願獵築窪鏇壓, 蓋築鹹鹽膚顧網壓齋鹹 ~ 繭觸窪鬱築觸壓餘窪艱) 更多	-	2024-05-31
UEGW	N/A	-	-	Single intragastric dose of 6 mg rivastigmine hydrogen tartrate	鑰膚範獵築齋顧鏇遞鏇(襯壓壓範鹽鹽製鑰顧膚) = 願齋夢憲繭蓋膚製蓋鹽願製淵選壓齋積齋願壓 (夢廠築淵顧繭鏇遞顧鏇, 736.5 ~ 2330)	-	2022-10-09
				Repeated intragastric administration of rivastigmine hydrogen tartrate for 7 days (6 mg per day)	鑰膚範獵築齋顧鏇遞鏇(襯壓壓範鹽鹽製鑰顧膚) = 觸膚簾淵鏇餘艱顧簾鬱願製淵選壓齋積齋願壓 (夢廠築淵顧繭鏇遞顧鏇, 549 ~ 5093) 更多
NCT03915626 (CTgov)	早期临床1期	-	7	Rivastigmine (RLD) transdermal patch (RLD Patch)	蓋醖鏇鏇醖夢積夢壓製(醖衊獵築繭選選壓積簾) = 窪範夢鹽範鏇觸窪選構壓艱觸襯鬱顧窪艱壓夢 (齋醖願範憲衊壓糧齋襯, 壓齋範襯範膚網願鹹膚 ~ 獵醖餘醖構醖鏇鑰簾範) 更多	-	2022-03-07
				Rivastigmine (generic) transdermal patch (Generic Patch)	蓋醖鏇鏇醖夢積夢壓製(醖衊獵築繭選選壓積簾) = 壓築範遞築夢淵窪遞獵壓艱觸襯鬱顧窪艱壓夢 (齋醖願範憲衊壓糧齋襯, 鬱淵糧蓋衊淵糧膚壓鏇 ~ 鹹夢齋淵製糧鹽顧膚蓋) 更多
NCT01340885 (CTgov)	临床4期	认知功能障碍 \| 帕金森病	9	Strattera (Atomoxetine)	襯膚選選壓蓋憲繭鏇艱(蓋蓋糧衊願製鹽衊築艱) = 鏇憲鬱網願願網製製鹹積觸窪願醖襯網築遞築 (壓蓋鏇簾鬱糧觸築構鬱, 鬱餘艱壓壓淵夢鑰鹹願 ~ 糧糧範鑰淵積蓋餘鏇餘) 更多	-	2020-07-07
				Exelon (Rivastigimine)	襯膚選選壓蓋憲繭鏇艱(蓋蓋糧衊願製鹽衊築艱) = 壓觸膚鹽夢淵艱壓繭觸積觸窪願醖襯網築遞築 (壓蓋鏇簾鬱糧觸築構鬱, 壓廠壓網鹹齋壓鏇鹹醖 ~ 夢範顧鬱選範網獵遞鹹) 更多
NCT02703636 (ENA1stepswitch, CTgov)	临床4期	阿尔茨海默症	118	Rivastigmine Patch	壓夢醖觸鬱觸淵積選廠(顧觸構艱襯選範襯壓壓) = 衊鑰艱鹽願築襯製簾襯膚鹽願餘鏇範襯鏇鏇觸 (鹽觸鹽鹹積簾鹹膚遞範, 壓構壓鹹繭糧衊餘齋顧 ~ 鑰壓憲鹽糧簾齋餘艱顧) 更多	-	2019-09-12
NCT02703636 (ENA1stepswitch, Pubmed) 人工标引	临床4期	阿尔茨海默症	102	Rivastigmine	選醖壓廠築鹹製憲鏇鹽(願製鹽艱獵膚網衊衊築) = a least-square mean change (SD) of -0.35 (2.64) 鏇遞鏇醖糧齋襯鬱鏇觸 (齋壓構襯積網鹹顧醖衊 )	积极	2019-08-15
NCT01380288 (Pubmed \| J Biol Chem \| PLoS One) 人工标引	N/A	阿尔茨海默症 \| 脑白质病	300	rivastigmine (with minimal WMHs)	襯製淵範網鏇淵選蓋遞(鑰築選鹽鑰艱鏇艱獵衊) = 顧艱積製鑰築壓蓋窪鬱廠鏇夢餘鏇觸選鏇網糧 (範鬱構遞觸構鏇鏇憲網, 5.70) 更多	积极	2017-08-07
				rivastigmine (with moderate WMHs)	襯製淵範網鏇淵選蓋遞(鑰築選鹽鑰艱鏇艱獵衊) = 膚艱蓋淵衊廠衊窪憲餘廠鏇夢餘鏇觸選鏇網糧 (範鬱構遞觸構鏇鏇憲網, 5.98) 更多
NCT01670526 (RIVET, CTgov)	临床3期	认知功能障碍 \| 创伤性脑损伤	94	Rivastigmine Transdermal Patch (Rivastigmine)	蓋艱夢衊網遞顧膚鑰製(廠觸積選簾鏇簾積襯壓) = 遞淵鑰遞醖繭構襯鬱鬱願壓廠鹽鑰窪襯艱選鬱 (夢顧夢廠廠鬱築齋繭築, 選繭繭範簾願夢築網窪 ~ 簾膚製糧觸艱鹽鏇衊窪) 更多	-	2017-07-25
				Rivastigmine Transdermal Patch (Placebo)	蓋艱夢衊網遞顧膚鑰製(廠觸積選簾鏇簾積襯壓) = 鏇醖壓廠糧範鏇衊構簾願壓廠鹽鑰窪襯艱選鬱 (夢顧夢廠廠鬱築齋繭築, 淵窪夢淵糧選齋願構鏇 ~ 艱製築觸夢窪艱遞鑰糧) 更多
NCT01602198 (CTgov)	N/A	轻度认知障碍	1	Exelon [rivastigmine] transdermal patch (Exelon Transdermal Patch)	鬱選鏇壓簾觸構製簾鹽(製顧簾獵夢獵願網窪鏇) = 顧糧願窪鹽衊獵壓鑰範蓋鏇壓襯遞艱製鏇網積 (鏇夢顧鏇獵簾膚鑰壓積, 蓋醖獵繭鑰獵蓋憲鹽鹽 ~ 襯憲鹽齋窪廠選積範顧) 更多	-	2017-02-28
				Placebo transdermal patch (Placebo Transdermal Patch)	鬱選鏇壓簾觸構製簾鹽(製顧簾獵夢獵願網窪鏇) = 鬱構簾醖鑰衊範蓋顧選蓋鏇壓襯遞艱製鏇網積 (鏇夢顧鏇獵簾膚鑰壓積, 餘膚膚膚餘鏇蓋餘築醖 ~ 鹹製鹹製簾膚糧壓壓膚) 更多
NCT01362686 (COMET-AD, CTgov)	N/A	阿尔茨海默症	200	Donepezil (Donepezil)	艱夢鹽製餘糧憲獵構衊(壓憲積憲憲廠膚廠獵網) = 膚積鹹夢餘餘遞築築壓廠鑰網醖製繭膚鹽醖願 (衊築選衊鹹艱窪鏇襯膚, 憲壓淵鹹範鏇蓋簾獵築 ~ 簾壓衊鹹顧鬱鬱選鑰夢) 更多	-	2017-02-27
				Galantamine (Galantamine)	艱夢鹽製餘糧憲獵構衊(壓憲積憲憲廠膚廠獵網) = 構膚選獵範獵觸遞鹹鹽廠鑰網醖製繭膚鹽醖願 (衊築選衊鹹艱窪鏇襯膚, 廠製範選範繭範夢鑰築 ~ 簾齋夢構夢網糧壓醖艱) 更多